Global 코인 카지노 사이트 development experts to speak at symposium, boosting 코인 카지노 사이트 development capabilities
[by Ji, Yong Jun] ABL Bio announced on March 10 that it will host an ‘Antibody-Drug Conjugate (코인 카지노 사이트) Symposium’ for professionals in the biotechnology industry on the upcoming March 14.
The 코인 카지노 사이트 Symposium was convened to strengthen 코인 카지노 사이트 development capabilities, a key focus in the field of anticancer drug research, and to promote knowledge exchange among Korean and international experts in 코인 카지노 사이트 development. The symposium will feature presentations by 코인 카지노 사이트 specialists with extensive experience in the development of 코인 카지노 사이트s at leading global pharmaceutical and biotechnology companies.
The first session, titled ‘The Past, Present, and Future of 코인 카지노 사이트s,’ will be led by Dr. Mark Sliwkowski from Genentech, a biotech company under the Roche Group. During the session, Dr. Sliwkowski will discuss the history of 코인 카지노 사이트s, the success of the HER2-targeting 코인 카지노 사이트 ‘K코인 카지노 사이트yla’, and his experiences with developing unsuccessful 코인 카지노 사이트 candidates.
The second session, titled ‘코인 카지노 사이트 for Oncology Treatment,’ will be presented by Dr. Peter Senter from Seagen and Bristol Myers Squibb, who was involved in the approval for 코인 카지노 사이트 drugs such as ‘P코인 카지노 사이트ev’ and ‘Tivdak’.
The third session, titled ‘Sharing Insights on 코인 카지노 사이트 Clinical Development’, will be conducted by Dr. Patrick Zweidler-McKay, who will discuss clinical development cases of 코인 카지노 사이트s targeting solid tumor patients, as well as the therapeutic benefits of 코인 카지노 사이트. Dr. Zweidler-McKay, formerly with Immunogen, the developer of ‘Elahere’, a folate receptor alpha (FRα) 코인 카지노 사이트, is now a consultant at Zweidler-McKay Consulting.
The fourth session, titled ‘Late-stage 코인 카지노 사이트 Pipeline Development Strategy,’ will feature Immunomedics, the developer of the 코인 카지노 사이트 targeting TROP2, ‘Trodelvy,’ along with Dr. Morris Rosenberg from Seagen (formerly Seattle Genetics). They will introduce strategies for late-stage 코인 카지노 사이트 development.
The fifth and sixth sessions will address key considerations in the development of 코인 카지노 사이트s in the non-clinical stage, as well as 코인 카지노 사이트 clinical pharmacology. Dr. Laurie Tatalick, co-founder of ProfoundBio, and Dr. Tae Han from Seagen will serve as the speakers for these sessions.
The seventh session will feature Kai Ming-Pu, a consultant from ClearView, a global consulting firm specializing in healthcare, who will present on new trends in 코인 카지노 사이트 development.
In July 2024, ABL Bio initiated the development of dual antibody 코인 카지노 사이트s and conducted a third-party allocation paid-in capital increase worth KRW 140 billion (approximately USD 96.2 million). The company is currently recruiting executives and 코인 카지노 사이트 development experts to strengthen the capabilities of ‘ABL Bio USA,’ the U.S. subsidiary responsible for developing dual antibody 코인 카지노 사이트s. ABL Bio plans to begin submitting clinical trial plans (IND) for its dual antibody 코인 카지노 사이트s starting at the end of this year.
“As the importance of 코인 카지노 사이트s in anticancer drug development continues to grow, we have invited international 코인 카지노 사이트 experts to strengthen the capabilities of our researchers and other professionals in the biotechnology industry,” said Lee Sang-hoon, CEO of ABL Bio. “We have organized this event with great care to support practical 코인 카지노 사이트 research and development (R&D), and we hope for your continued interest.”